Antenatal magnesium sulfate for both tocolysis and fetal neuroprotection in premature rupture of the membranes before 32 weeks’ gestation

References

• Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84.
   PubMed Web of Science ®Google Scholar
• Epstein FH, Parry S, Strauss JF. Premature rupture of the fetal membranes. N Engl J Med. 1998;338:663–670.
   PubMed Web of Science ®Google Scholar
• Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101:178–193.
   PubMed Web of Science ®Google Scholar
• Fox NS, Gelber SE, Kalish RB, et al. Contemporary practice patterns and beliefs regarding tocolysis among u.s. maternal-fetal medicine specialists. Obstet Gynecol. 2008;112:42–47.
   PubMed Web of Science ®Google Scholar
• Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;1:CD004661.
   PubMed Web of Science ®Google Scholar
• Grether JK, Hoogstrate J, Walsh-Greene E, et al. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol. 2000;183:717–725.
   PubMed Web of Science ®Google Scholar
• Rouse DJ. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol. 2009;200:610–612.
   PubMed Web of Science ®Google Scholar
• Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol. 1991;164:1317–1326.
   PubMed Web of Science ®Google Scholar
• Cunningham FG. Overview of obstetrics. In: Cunningham FG. Leveno KJ, Bloom SL, et al., editors. Williams Obstetrics. 24th ed. New York: McGraw-Hill; 2014. p. 24.
   Google Scholar
• Papile L, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. J Pediatr. 1978;92:529–534.
   PubMed Web of Science ®Google Scholar
• Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.
   PubMed Web of Science ®Google Scholar
• Harding JE, Pang J, Knight DB, et al. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol. 2001;184:131–139.
   PubMed Web of Science ®Google Scholar
• Mercer BM, Crocker LG, Boe NM, et al. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol. 1993;169:775–782.
   PubMed Web of Science ®Google Scholar
• Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2011;10:CD007062.
   Google Scholar
• Crowther C, Hiller J, Doyle L. Magnesium sulphate for preventing preterm birth in threatened preterm labour (review). Cochrane Database Syst Rev. 2002;4:CD001060.
   Google Scholar
• Ehsanipoor RM, Shrivastava VK, Lee RM, et al. A randomized, double-masked trial of prophylactic indomethacin tocolysis versus placebo in women with premature rupture of membranes. Amer J Perinatol. 2011;28:473–478.
   PubMed Web of Science ®Google Scholar
• Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359:895–905.
   PubMed Web of Science ®Google Scholar
• Doyle LW. and Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics. 2001;108:134–141.
   PubMed Web of Science ®Google Scholar
• Doyle L, Bowman E, Callanan C, et al. Outcome at 2 years of children 23-27 weeks’ gestation born in victoria in 1991–92. J Paediatr Child Health. 1997;33:161–165.
   PubMed Web of Science ®Google Scholar
• Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA. 2000;284:1417–1424.
   PubMed Web of Science ®Google Scholar
• Mittendorf R, Pryde PG. An overview of the possible relationship between antenatal pharmacologic magnesium and cerebral palsy. J Perinat Med. 2000;28:286–293.
   PubMed Web of Science ®Google Scholar
• Hallak M, Irtenkauf SM, Cotton DB. Effect of magnesium sulfate on excitatory amino acid receptors in the rat brain. Am J Obstet Gynecol. 1996;175:582–587.
   PubMed Web of Science ®Google Scholar
• Rhee E, James A, Walker C, et al. 260 maternal and fetal platelet function after maternal exposure to magnesium sulfate. Am J Obstet Gynecol. 2001;185:S151.
   Web of Science ®Google Scholar
• Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669–2676.
   PubMed Web of Science ®Google Scholar
• King JF, Flenady V, Papatsonis D, et al. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev. 2003;1:CD002255.
   Google Scholar
• Anotayanonth S, Subhedar NV, Garner P, et al. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev. 2004;4:CD004352.
   Web of Science ®Google Scholar
• Mercer BM, Merlino AA. Society for Maternal-Fetal Medicine. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol. 2009;114:650–668.
   PubMed Web of Science ®Google Scholar
• Liston R, Sawchuck D, Young D. Society of obstetrics and gynaecologists of Canada, British Columbia perinatal health program. Fetal health surveillance: antepartum and intrapartum consensus guideline. J Obstet Gynaecol Can. 2007;29:S3–S56.
   PubMedGoogle Scholar
• Food and Drug Administration. FDA Recommends Against Prolonged use of Magnesium Sulfate to Stop Pre-Term Labor due to Bone Changes in Exposed Babies. FDA Drug Safety Communication. FDA; 2013.
   Google Scholar